Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy

Linda L. Carpenter, Lily Bayat, Francisco Moreno, Mitchel A. Kling, Lawrence H. Price, Audrey R. Tyrka, Becky Kinkead, Michael J. Owens, Charles Nemeroff

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Recent preclinical and clinical research has demonstrated that the neuropeptide substance P (SP) plays a role in the central nervous system (CNS) response to stress, and perhaps in the etiology of major depression and/or anxiety disorders. The nature of this role, however, is poorly understood. A limited body of evidence suggests that in medication-free depressed patients, cerebrospinal fluid (CSF) concentrations of SP may be elevated relative to healthy controls. Two studies have shown that antidepressant treatment does not significantly change CSF concentrations of SP. Using standard lumbar puncture techniques, baseline CSF samples were obtained from 19 medication-free healthy controls and 19 medicated patients with treatment-resistant depression (TRD). Mean CSF SP concentration was significantly lower in TRD patients on psychotropic medications than in the group of healthy subjects. After 10-12 weeks of treatment with adjunct vagus nerve stimulation (VNS), CSF SP concentrations were not significantly changed. Low CSF SP may reflect a biological marker of the subtype of severe and chronic depression that is resistant to standard therapies.

Original languageEnglish
Pages (from-to)123-129
Number of pages7
JournalPsychiatry Research
Volume157
Issue number1-3
DOIs
StatePublished - Jan 15 2008
Externally publishedYes

Fingerprint

Treatment-Resistant Depressive Disorder
Vagus Nerve Stimulation
Substance P
Cerebrospinal Fluid
Therapeutics
Depression
Spinal Puncture
Anxiety Disorders
Neuropeptides
Antidepressive Agents
Healthy Volunteers
Central Nervous System
Biomarkers
Research

Keywords

  • Cerebrospinal fluid
  • Substance P
  • Treatment-resistant depression
  • Vagus nerve stimulation

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Cite this

Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. / Carpenter, Linda L.; Bayat, Lily; Moreno, Francisco; Kling, Mitchel A.; Price, Lawrence H.; Tyrka, Audrey R.; Kinkead, Becky; Owens, Michael J.; Nemeroff, Charles.

In: Psychiatry Research, Vol. 157, No. 1-3, 15.01.2008, p. 123-129.

Research output: Contribution to journalArticle

Carpenter, Linda L. ; Bayat, Lily ; Moreno, Francisco ; Kling, Mitchel A. ; Price, Lawrence H. ; Tyrka, Audrey R. ; Kinkead, Becky ; Owens, Michael J. ; Nemeroff, Charles. / Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. In: Psychiatry Research. 2008 ; Vol. 157, No. 1-3. pp. 123-129.
@article{b885d8aaa53b46aab793cd335c5c7eaa,
title = "Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy",
abstract = "Recent preclinical and clinical research has demonstrated that the neuropeptide substance P (SP) plays a role in the central nervous system (CNS) response to stress, and perhaps in the etiology of major depression and/or anxiety disorders. The nature of this role, however, is poorly understood. A limited body of evidence suggests that in medication-free depressed patients, cerebrospinal fluid (CSF) concentrations of SP may be elevated relative to healthy controls. Two studies have shown that antidepressant treatment does not significantly change CSF concentrations of SP. Using standard lumbar puncture techniques, baseline CSF samples were obtained from 19 medication-free healthy controls and 19 medicated patients with treatment-resistant depression (TRD). Mean CSF SP concentration was significantly lower in TRD patients on psychotropic medications than in the group of healthy subjects. After 10-12 weeks of treatment with adjunct vagus nerve stimulation (VNS), CSF SP concentrations were not significantly changed. Low CSF SP may reflect a biological marker of the subtype of severe and chronic depression that is resistant to standard therapies.",
keywords = "Cerebrospinal fluid, Substance P, Treatment-resistant depression, Vagus nerve stimulation",
author = "Carpenter, {Linda L.} and Lily Bayat and Francisco Moreno and Kling, {Mitchel A.} and Price, {Lawrence H.} and Tyrka, {Audrey R.} and Becky Kinkead and Owens, {Michael J.} and Charles Nemeroff",
year = "2008",
month = "1",
day = "15",
doi = "10.1016/j.psychres.2007.04.016",
language = "English",
volume = "157",
pages = "123--129",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "1-3",

}

TY - JOUR

T1 - Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy

AU - Carpenter, Linda L.

AU - Bayat, Lily

AU - Moreno, Francisco

AU - Kling, Mitchel A.

AU - Price, Lawrence H.

AU - Tyrka, Audrey R.

AU - Kinkead, Becky

AU - Owens, Michael J.

AU - Nemeroff, Charles

PY - 2008/1/15

Y1 - 2008/1/15

N2 - Recent preclinical and clinical research has demonstrated that the neuropeptide substance P (SP) plays a role in the central nervous system (CNS) response to stress, and perhaps in the etiology of major depression and/or anxiety disorders. The nature of this role, however, is poorly understood. A limited body of evidence suggests that in medication-free depressed patients, cerebrospinal fluid (CSF) concentrations of SP may be elevated relative to healthy controls. Two studies have shown that antidepressant treatment does not significantly change CSF concentrations of SP. Using standard lumbar puncture techniques, baseline CSF samples were obtained from 19 medication-free healthy controls and 19 medicated patients with treatment-resistant depression (TRD). Mean CSF SP concentration was significantly lower in TRD patients on psychotropic medications than in the group of healthy subjects. After 10-12 weeks of treatment with adjunct vagus nerve stimulation (VNS), CSF SP concentrations were not significantly changed. Low CSF SP may reflect a biological marker of the subtype of severe and chronic depression that is resistant to standard therapies.

AB - Recent preclinical and clinical research has demonstrated that the neuropeptide substance P (SP) plays a role in the central nervous system (CNS) response to stress, and perhaps in the etiology of major depression and/or anxiety disorders. The nature of this role, however, is poorly understood. A limited body of evidence suggests that in medication-free depressed patients, cerebrospinal fluid (CSF) concentrations of SP may be elevated relative to healthy controls. Two studies have shown that antidepressant treatment does not significantly change CSF concentrations of SP. Using standard lumbar puncture techniques, baseline CSF samples were obtained from 19 medication-free healthy controls and 19 medicated patients with treatment-resistant depression (TRD). Mean CSF SP concentration was significantly lower in TRD patients on psychotropic medications than in the group of healthy subjects. After 10-12 weeks of treatment with adjunct vagus nerve stimulation (VNS), CSF SP concentrations were not significantly changed. Low CSF SP may reflect a biological marker of the subtype of severe and chronic depression that is resistant to standard therapies.

KW - Cerebrospinal fluid

KW - Substance P

KW - Treatment-resistant depression

KW - Vagus nerve stimulation

UR - http://www.scopus.com/inward/record.url?scp=36448970518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36448970518&partnerID=8YFLogxK

U2 - 10.1016/j.psychres.2007.04.016

DO - 10.1016/j.psychres.2007.04.016

M3 - Article

VL - 157

SP - 123

EP - 129

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 1-3

ER -